Noile-Immune Biotech Inc. [4893.T]
TOKYO, Mar 31 (Pulse News Wire) – Noile-Immune Biotech Inc. (4893.T) outlined its plans to develop its CAR-T therapy pipeline, targeting various cancer types such as small-cell lung cancer and triple-negative breast cancer.
The company expects to address a potential patient population of up to 93,976 people globally by 2026. In 2025, Noile-Immune reported a revenue of ¥625 million and an operating loss of ¥316 million. With a capital of ¥4.047 billion as of December 2025, the firm aims to allocate funds towards advancing its pipeline projects, including NIB101, NIB103, and subsequent non-clinical trials.
The company's growth strategy includes expanding its research efforts and securing partnerships to optimize its portfolio. It also plans to commercialize products overseas and achieve profitability through milestone payments and licensing deals. However, Noile-Immune acknowledges risks associated with clinical trial outcomes and intellectual property disputes.
🟢 Confidence: High AI-translated content.